Lidocaine 2% (preservative-free, without vasoconstrictor): Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor, 1.8 ml at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.
Lidocaine 2% + Magnesium Sulfate 10% (combination): Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor mixed with 10%magnesium sulphate , Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄) at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.
Study summary
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age between 18 and 70 years.
2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
4. Pain duration ≥ 3 months.
5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
6. Noprior trigger point injection in the affected area within the past 3 months.
7. Ability and willingness to provide informed consent.
8. Compliance with study visits and procedures
Exclusion Criteria:
1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
2. Current use of anticoagulants or history of bleeding disorders.
3. Systemic or local infection at or near the injection site.
4. History of fibromyalgia, central pain syndromes, or cancer-related pain.
5. Major psychiatric illnesses (e.g., schizophrenia, severe depression).
6. Recent surgery or trauma to the head, neck, or upper back (\<6 months).
7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention.
8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
Primary outcome measure(s)
Pain reduction. — Baseline, 1week, 2 weeks post-injection. Pain intensity will be assessed using the Visual Analogue Scale (VAS) ranging from 0 to 10 cm, where 0 indicates no pain and 10 indicates worst imaginable pain.
Muscle activity improvement. — Baseline, 1 week, 2 weeks post-injection Muscle activity will be assessed using surface electromyography (sEMG) by measuring Maximum Voluntary Contraction (MVC) in microvolts (µV). Higher values indicate improved muscle activity.
Trial sites (1)
Facility
City
Region
Status
Faculty of oral and dental medicine, cairo university
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.